WO2005037312A3 - Bindemoleküle für die extra-domäne b von fibronectin zur detektion von atherosklerotischen plaques - Google Patents

Bindemoleküle für die extra-domäne b von fibronectin zur detektion von atherosklerotischen plaques Download PDF

Info

Publication number
WO2005037312A3
WO2005037312A3 PCT/EP2004/011654 EP2004011654W WO2005037312A3 WO 2005037312 A3 WO2005037312 A3 WO 2005037312A3 EP 2004011654 W EP2004011654 W EP 2004011654W WO 2005037312 A3 WO2005037312 A3 WO 2005037312A3
Authority
WO
WIPO (PCT)
Prior art keywords
fibronectin
extra
domain
detection
atherosclerotic plaques
Prior art date
Application number
PCT/EP2004/011654
Other languages
English (en)
French (fr)
Other versions
WO2005037312A2 (de
Inventor
Dieter Heldmann
Original Assignee
Schering Ag
Dieter Heldmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag, Dieter Heldmann filed Critical Schering Ag
Priority to EP04790493A priority Critical patent/EP1684804A2/de
Priority to JP2006534712A priority patent/JP4755103B2/ja
Publication of WO2005037312A2 publication Critical patent/WO2005037312A2/de
Publication of WO2005037312A3 publication Critical patent/WO2005037312A3/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Die vorliegende Erfindung betrifft die Verwendung von markierten L19-Derivaten zur Herstellung einer pharmazeutischen Zusammensetzung zur Detektion von atherosklerotischen Plaques.
PCT/EP2004/011654 2003-10-17 2004-10-15 Bindemoleküle für die extra-domäne b von fibronectin zur detektion von atherosklerotischen plaques WO2005037312A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04790493A EP1684804A2 (de) 2003-10-17 2004-10-15 Bindemoleküle für die extra-domäne b von fibronectin zur detektion von atherosklerotischen plaques
JP2006534712A JP4755103B2 (ja) 2003-10-17 2004-10-15 動脈硬化性プラークの検出のために使用されるフィブロネクチンのドメインｂ外ドメインのための結合分子

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10348319.5 2003-10-17
DE10348319A DE10348319A1 (de) 2003-10-17 2003-10-17 Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques

Publications (2)

Publication Number Publication Date
WO2005037312A2 WO2005037312A2 (de) 2005-04-28
WO2005037312A3 true WO2005037312A3 (de) 2005-06-23

Family

ID=34442038

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/011654 WO2005037312A2 (de) 2003-10-17 2004-10-15 Bindemoleküle für die extra-domäne b von fibronectin zur detektion von atherosklerotischen plaques

Country Status (5)

Country Link
US (1) US20050112690A1 (de)
EP (1) EP1684804A2 (de)
JP (1) JP4755103B2 (de)
DE (1) DE10348319A1 (de)
WO (1) WO2005037312A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4243201A (en) * 2000-02-24 2001-09-03 Eidgenoess Tech Hochschule Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
WO2008046510A1 (en) * 2006-10-16 2008-04-24 Bayer Healthcare Ag Fn1 as a biomarker, therapeutic and diagnostic target
EP1917980A1 (de) * 2006-10-31 2008-05-07 Bayer Schering Pharma Aktiengesellschaft Verwendung eines Fusionproteins zwischen einer Zytokine und einem Antikörper gegen die ED-B Fibronektin Domäne zur Behandlung von Atherosklerosis
WO2011110490A1 (en) 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft Process for the production of radioactively labelled scfv antibody fragments, kits and compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062800A1 (en) * 2000-02-24 2001-08-30 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
WO2003055917A2 (en) * 2002-01-03 2003-07-10 Schering Aktiengesellschaft Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062800A1 (en) * 2000-02-24 2001-08-30 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
WO2003055917A2 (en) * 2002-01-03 2003-07-10 Schering Aktiengesellschaft Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CASTELLANI PATRIZIA ET AL: "Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin", AMERICAN JOURNAL OF PATHOLOGY, vol. 161, no. 5, November 2002 (2002-11-01), pages 1695 - 1700, XP002319107, ISSN: 0002-9440 *
DEMARTIS S ET AL: "Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin", EUROPEAN JOURNAL OF NUCLEAR MEDICINE, BERLIN, DE, vol. 28, no. 4, April 2001 (2001-04-01), pages 534 - 539, XP001184113, ISSN: 0340-6997 *
GLUKHOVA M A ET AL: "Expression of fibronectin variants in vascular and visceral smooth muscle cells in development.", DEVELOPMENTAL BIOLOGY. SEP 1990, vol. 141, no. 1, September 1990 (1990-09-01), pages 193 - 202, XP009044428, ISSN: 0012-1606 *
MAGNUSSON M K ET AL: "Fibronectin: structure, assembly, and cardiovascular implications.", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY. SEP 1998, vol. 18, no. 9, September 1998 (1998-09-01), pages 1363 - 1370, XP002319106, ISSN: 1079-5642 *
WILSON STEPHANIE H ET AL: "Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering.", CIRCULATION. 29 JAN 2002, vol. 105, no. 4, 29 January 2002 (2002-01-29), pages 415 - 418, XP002319108, ISSN: 1524-4539 *

Also Published As

Publication number Publication date
DE10348319A1 (de) 2005-05-19
EP1684804A2 (de) 2006-08-02
US20050112690A1 (en) 2005-05-26
WO2005037312A2 (de) 2005-04-28
JP4755103B2 (ja) 2011-08-24
JP2007508352A (ja) 2007-04-05

Similar Documents

Publication Publication Date Title
WO2007120265A3 (en) Coded molecules for detecting target analytes
IL186279A0 (en) Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the new synthesis of (s)-pregabalin
NO2014009I2 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser
WO2003093269A3 (de) Substituierte pyrazolo-pyrimidin-4-one
DE502006006854D1 (de) Substituierte benzo (d) isoaxol-3-yl-amin-verbindungen als analgetika
WO2006130551A3 (en) Luminogenic and fluorogenic compounds and methods to detect molecules or conditions
WO2005073722A3 (en) Luminogenic and nonluminogenic multiplex assay
GB2431927A9 (en) 1,2-Disubstituted indoles & derivatives thereof astherapeutic 5-iipoxygenase-activating protein (fl ap) inhibitors
ZA200804489B (en) 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as PTP-AS inhibitors
PL1877415T3 (pl) Nowe strategie znakowania dla czułego wykrywania analitów
IL185419A0 (en) Improved process for the synthesis of enantiomeric indanylamine derivatives
WO2005121078A3 (de) Substituierte cyclopenten-verbindungen
PT1713801E (pt) Processo para a preparação de 1-(2s,3s)-2-benzidril-n-(5- -terc-butil-2-metoxibenzil)-quinuclidina-3-amina
WO2007047671A3 (en) Tetrahydroquinolines, synthesis thereof, and intermediates thereto
WO2006074334A3 (en) Identification of rna targets using helicases
WO2007016029A3 (en) Diazepinoquinolines, synthesis thereof, and intermediates thereto
WO2008079266A3 (en) Synthesis of pyrrolidine compounds
WO2007002722A3 (en) Synthesis of anastrozole and purification of one of its intermediate
WO2006122777A3 (de) Verwendung von 2,5-disubstituierten thiazol-4-on-derivaten in arzneimitteln
WO2008019356A3 (en) Process for the preparation of substituted-1,2,3,4-tetrahydroisoquinoline derivates
NO20050885L (no) Ny fremgangsmate for syntesen av 1,3-dihydro-2H-3-benzazepin-2-onforbindelser, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
WO2005037312A3 (de) Bindemoleküle für die extra-domäne b von fibronectin zur detektion von atherosklerotischen plaques
WO2004052881A3 (en) Process for preparing (s)-pantoprazole
EP1673437A4 (de) Zusammensetzungen und verfahren zum synthetisieren, aufreinigen und nachweisen von biomolekülen
NO20044050L (no) Fremgangsmate for syntese av chirale N-aryl-piperaziner

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004790493

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006534712

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004790493

Country of ref document: EP